302 related articles for article (PubMed ID: 33298653)
1. [Successful disease control of plasma cell leukemia by the treatment comprising proteasome inhibitors, followed by daratumumab, lenalidomide, and dexamethasone therapy].
Nakamura A; Yamaguchi T; Ito R; Kawakami K
Rinsho Ketsueki; 2020; 61(11):1600-1604. PubMed ID: 33298653
[TBL] [Abstract][Full Text] [Related]
2. Disseminated Cryptococcosis in a Patient with Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone.
Sato S; Kambe E; Tamai Y
Intern Med; 2019 Mar; 58(6):843-847. PubMed ID: 30449801
[TBL] [Abstract][Full Text] [Related]
3. Renal recovery following daratumumab, lenalidomide, and dexamethasone therapy in a patient with newly diagnosed dialysis-dependent multiple myeloma.
Mizuno S; Kitayama C; Mashiko S; Sanada S
CEN Case Rep; 2022 May; 11(2):265-268. PubMed ID: 34817845
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma.
Xu XS; Dimopoulos MA; Sonneveld P; Ho PJ; Belch A; Leiba M; Capra M; Gomez D; Medvedova E; Iida S; Min CK; Schecter J; Jansson R; Zhang L; Sun YN; Clemens PL
Adv Ther; 2018 Nov; 35(11):1859-1872. PubMed ID: 30374808
[TBL] [Abstract][Full Text] [Related]
5. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Plesner T; Arkenau HT; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Laubach JP; Palumbo A; Lisby S; Basse L; Wang J; Sasser AK; Guckert ME; de Boer C; Khokhar NZ; Yeh H; Clemens PL; Ahmadi T; Lokhorst HM; Richardson PG
Blood; 2016 Oct; 128(14):1821-1828. PubMed ID: 27531679
[TBL] [Abstract][Full Text] [Related]
6. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse.
Montefusco V; Corso A; Galli M; Ardoino I; Pezzatti S; Carniti C; Patriarca F; Gherlinzoni F; Zambello R; Sammassimo S; Marcatti M; Nozza A; Crippa C; Cafro AM; Baldini L; Corradini P
Br J Haematol; 2020 Mar; 188(6):907-917. PubMed ID: 31898319
[TBL] [Abstract][Full Text] [Related]
8. Successful bortezomib/dexamethasone induction therapy with lenalidomide in an elderly patient with primary plasma cell leukemia complicated by renal failure and pulmonary hypertension.
Tamura S; Koyama A; Shiotani C; Kurihara T; Nishikawa A; Okamoto Y; Fujimoto T
Intern Med; 2014; 53(11):1171-5. PubMed ID: 24881743
[TBL] [Abstract][Full Text] [Related]
9. Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by "rete ematologica pugliese".
Mele G; Di Renzo N; Cascavilla N; Carella AM; Guarini A; Mazza P; Melillo L; Pavone V; Tarantini G; Curci P; Falcone AP; Germano C; Mele A; Merchionne F; Palazzo G; Palumbo G; Quinto AM; Reddiconto G; Rossini B; Spina A; Sgherza N; Specchia G; Musto P; Pastore D
Leuk Lymphoma; 2023 Oct; 64(10):1715-1718. PubMed ID: 37417467
[No Abstract] [Full Text] [Related]
10. Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma.
Zhang TT; Wang S; Wan N; Zhang L; Zhang Z; Jiang J
Clin Ther; 2018 Jul; 40(7):1122-1139. PubMed ID: 30006069
[TBL] [Abstract][Full Text] [Related]
11. [Successful treatment of myelomatous pleural effusion with daratumumab administration before autologous peripheral stem cell transplantation].
Wada A; Yasumura S; Kajikawa S; Murakami J; Sato T
Rinsho Ketsueki; 2020; 61(8):879-884. PubMed ID: 32908050
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials.
Zheng Y; Shen H; Xu L; Feng J; Tang H; Zhang N; Chen X; Gao G
J Immunol Res; 2018; 2018():7646913. PubMed ID: 30050957
[TBL] [Abstract][Full Text] [Related]
14. A case of allogeneic hematopoietic stem cell transplantation for primary plasma cell leukemia after treatment with daratumumab.
Horisawa Y; Kondo T; Hishizawa M; Yamashita K; Takaori-Kondo A
Ann Hematol; 2020 Nov; 99(11):2699-2701. PubMed ID: 32318778
[No Abstract] [Full Text] [Related]
15. Daratumumab plus lenalidomide and dexamethasone
Dimopoulos MA; San-Miguel J; Belch A; White D; Benboubker L; Cook G; Leiba M; Morton J; Ho PJ; Kim K; Takezako N; Moreau P; Kaufman JL; Sutherland HJ; Lalancette M; Magen H; Iida S; Kim JS; Prince HM; Cochrane T; Oriol A; Bahlis NJ; Chari A; O'Rourke L; Wu K; Schecter JM; Casneuf T; Chiu C; Soong D; Sasser AK; Khokhar NZ; Avet-Loiseau H; Usmani SZ
Haematologica; 2018 Dec; 103(12):2088-2096. PubMed ID: 30237262
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib, Lenalidomide, and Dexamethasone in Elderly Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.
Chahine C; Roos-Weil D; Saada V; de Botton S; Micol JB; Barete S; Marzac C; Ghez D
Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):e986-e989. PubMed ID: 32917576
[No Abstract] [Full Text] [Related]
17. FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy.
Bhatnagar V; Gormley NJ; Luo L; Shen YL; Sridhara R; Subramaniam S; Shen G; Ma L; Shord S; Goldberg KB; Farrell AT; McKee AE; Pazdur R
Oncologist; 2017 Nov; 22(11):1347-1353. PubMed ID: 28904172
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment with daratumumab, lenalidomide, and dexamethasone therapy followed by autologous stem cell transplantation for newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome: a case report.
Taenaka R; Shimokawa S; Katayama A; Nagao T; Obara T; Nishimura N; Tsujimoto A; Kohno K; Aoki K; Ogawa R
J Med Case Rep; 2022 Aug; 16(1):311. PubMed ID: 35978379
[TBL] [Abstract][Full Text] [Related]
19. Stringent complete remission of primary plasma cell leukemia with reduced-dose bortezomib, lenalidomide and dexamethasone: a case report and review of the literature.
Ueda S; Kubo M; Matsuura N; Matsunaga H; Kataoka S; Maeda T; Inui Y; Kawata S; Kanakura Y
Intern Med; 2013; 52(11):1235-8. PubMed ID: 23728562
[TBL] [Abstract][Full Text] [Related]
20. Plasma Cell Leukemia with Successful Upfront Venetoclax in Combination with Allogeneic Transplantation.
Tang ASO; Ahmad Asnawi AW; Koh AZY; Chong SL; Liew PK; Selvaratnam V; Md Fauzi A; Lau NS; Tan SM
Am J Case Rep; 2023 Mar; 24():e938868. PubMed ID: 36882990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
